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Abstract
Background: Scleroderma (systemic sclerosis; SSc) is a clinically heterogeneous and often lethal acquired disorder of
the connective tissue that is characterized by vascular, immune/inflammatory and fibrotic manifestations. Tissue
fibrosis is the main cause of morbidity and mortality in SSc and an unmet medical challenge, mostly because of our
limited understanding of the molecular factors and signalling events that trigger and sustain disease progression.
Recent evidence has correlated skin fibrosis in SSc with stabilization of proto-oncogene Ha-Ras secondary to auto-
antibody stimulation of reactive oxygen species production. The goal of the present study was to explore the
molecular connection between Ha-Ras stabilization and collagen I production, the main read-out of fibrogenesis, in a
primary dermal fibroblast culture system that replicates the early stages of disease progression in SSc.
Results: Forced expression of proto-oncogene Ha-Ras in dermal fibroblasts demonstrated the promotion of an
immediate collagen I up-regulation, as evidenced by enhanced activity of a collagen I-driven luciferase reporter
plasmid and increased accumulation of endogenous collagen I proteins. Moreover, normal levels of Tgfb transcripts
and active transforming growth factor-beta (TGFb) implied Ha-Ras stimulation of the canonical Smad2/3 signalling
pathway independently of TGFb production or activation. Heightened Smad2/3 signalling was furthermore
correlated with greater Smad3 phosphorylation and Smad3 protein accumulation, suggesting that Ha-Ras may
target both Smad2/3 activation and turnover. Additional in vitro evidence excluded a contribution of ERK1/2
signalling to improper Smad3 activity and collagen I production in cells that constitutively express Ha-Ras.
Conclusions: Our study shows for the first time that constitutively elevated Ha-Ras protein levels can directly
stimulate Smad2/3 signalling and collagen I accumulation independently of TGFb neo-synthesis and activation. This
finding therefore implicates the Ha-Ras pathway with the early onset of fibrosis in SSc and implicitly identifies new
therapeutic targets in SSc.
Background
Wound healing is a complex and tightly regulated phy-
siological process that involves several different cell
types and a plethora of signalling molecules [1-3]. In the
early phase of this process, platelets brought by the
blood stream form a fibrin cloth at the site of injury
that blocks bleeding (haemostasis). Increased levels of
soluble signals, induced by the cell-mediated inflamma-
tory response, subsequently promote migration and pro-
liferation of angiogenic cells and activated fibroblasts
(myofibroblasts) that synthesize extracellular matrix
(ECM) proteins, chiefly collagen I [1]. By contracting
the newly synthesized ECM, myofibroblasts allow the
closure of the wound where the provisional matrix is
ultimately remodelled to form a scar [1]. Failure of myo-
fibroblasts to terminate the wound healing process
results in excessive accumulation and contraction of a
poorly organized ECM. Unopposed myofibroblasts acti-
vation in fibrotic conditions, such as scleroderma (SSc),
causes gradual and irreversible alteration of connective
tissue architecture with deleterious consequences for
organ function. In spite of significant investigative effort,
our current knowledge of the molecular and cellular
events that promote and sustain myofibroblasts activa-
tion is limited and consequently, the clinical manage-
ment of affected patients remains confined to therapies
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the often fatal consequences of the fibrotic response.
Clinical findings, cell culture experiments and animal
models have firmly established the prominent role that
transforming growth factor-b (TGFb) plays in modulat-
ing the physiological process of wound healing and in
driving the pathological sequence of fibrotic responses
[2,3]. Even though genetic or pharmacological interfer-
ence of TGFb signalling in rodents can mitigate fibrotic
disease, they can also result in severe side effects due to
the wide range of biological processes that involve this
multifunctional cytokine [2]. It follows that a better
understanding of molecular events upstream, down-
stream or parallel to improper TGFb signalling repre-
sents a pre-requisite to the development of more
effective and safer therapies for fibrotic conditions.
TGFb signals through the activation of a membrane-
receptor serine/threonine kinase complex that phos-
phorylates the Smad2 and Smad3 proteins [receptor-
activated Smads (R-Smad); canonical TGFb signalling
pathway] [4]. Activated R-Smad proteins associate with
Smad4 to migrate into the nucleus and modulate the
expression of several different genes together with
transcriptional co-activators and co-repressors [4]. In
addition to the canonical R-Smad pathway, TGFb can
also stimulate the activity of mitogen-activated protein
kinases (MAPKs; non-canonical TGFb signalling path-
way) and MAPKs and other stress response pathways
can, in turn, modulate R-Smad signalling with discrete
intracellular outcomes [5]. For example, the proto-
oncogene Ha-Ras can stimulate or inhibit R-Smad sig-
nalling, operate upstream of TGFb by promoting its
auto-induction or act independently of the canonical
TGFb signalling pathway [6-10]. Hence, complex interac-
tions amongst different signalling pathways are believed to
specify contextual responses of the cells to diverse environ-
mental stimuli.
The Ras gene family comprises three genetically dis-
tinct but structurally relatedp r o t e i n s( H a - R a s ,K i - R a s
and N-Ras), which operate as molecular switches that
cycle between an inactive GDP (guanosine dipho-
sphate)-bound to an active GTP (guanosine tripho-
sphate)-bound form [11]. Ras family members have
functionally distinct roles that are dictated by their
intracellular localization and the cellular context [11].
Ras signalling is the nodal point of multiple extracellular
cues, including the profibrotic signals of TGFb,a n g i o -
tensin II, platelet-derived growth factor (PDGF) and
reactive oxygen species (ROS) [7,12-14]. Recent studies
of SSc cells have causally connected circulating auto-
antibodies against PDGF receptors (PDGFR) with the
stimulation of ROS production, Ha-Ras stabilization and
collagen I overproduction [15,16]. However, the contri-
bution of Ha-Ras activity to SSc fibrogenesis, as well as
the cross-talk between Ha-Ras and TGFb signalling in
this disease process remains to be fully explored.
It was the scope of the present study to investigate the
pro-fibrotic potential of Ha-Ras signalling by using a cell
culture system that replicates the downstream events
previously described in SSc myofibroblasts. Our results
show for the first time that constitutively elevated Ha-
Ras protein levels promote R-Smad signalling and col-
lagen I accumulation independently of TGFb synthesis
and activation. These findings implicitly connect the
Ha-Ras pathway with the onset of fibrosis through the
stimulation of canonical TGFb pathway, even though
the biochemical identity of the connection was not
investigated here. More generally, our work provides
new insight into early disease-causing events that could
in principle represent new therapeutic targets in fibrotic
conditions like scleroderma.
Materials and methods
Cell cultures
Human fetal dermal fibroblasts (hDF; GM06111) were
purchased from the Human Genetic Mutant Cell Repo-
sitory (NJ, USA). Cells were maintained at 37°C in a
sterile and humidified atmosphere of 5% CO2.C e l l s
were grown in Dulbecco’s modified Eagle’sm e d i u m
(DMEM) containing 10% fetal bovine serum (FBS;
Atlanta Biologicals, GA, USA) and supplemented with
streptomycin, penicillin and fungizone. Primary mouse
dermal fibroblast (mDF) cultures were established from
t h ed o r s a ls k i no f4 - d a y - o l dw i l d - t y p em i c ea n dg r o w n
as described above. Several 8 mm sterile skin punches
were made from each newborn mice, freed of the subcu-
taneous tissue by scraping, and laid flat individually into
a 10-cm
2 tissue culture plate with the dermal side down.
Explants were incubated at 37°C for 5 min to let skin
adhere. Ten millilitres of medium was added into each
plate and cells were allowed to migrate out of the
explants for 10 days. Once confluent, cells were trypsi-
nized and either stored in liquid nitrogen or employed
immediately: in both cases, cells between passages 1 and
3 were used.
Cell transfections
Primary mDF and hDF were seeded the day before
transfection at a density of 10,000 cells/cm
2 and cul-
tured in 0.2% FBS. Cells were transiently co-transfected
using Lipofectamine 2000 (Invitrogen, CA, USA) with
0.5 ng of the control plasmid SV40:Renilla-Luc (Pro-
mega, WI, USA) and 200 ng of the COL1A2 (human
pro-a2 (I) collagen gene) reporter plasmid containing
wild-type or mutant TbRE (TGFb-responsive element)
sites [17] or the Smad3 responsive plasmid (CAGA)
12MLP-Luc (a kind gift of Dr Joan Massagué). In some
experiments, the COL1A2 reporter was transiently co-
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tutively active (V12 variant) proto-oncogene Ha-Ras
(Ha-Ras/pSG5 and ca-Ras/pSG5, respectively) or domi-
nant-negative (N17 variant) Ha-ras (DN-Ras/pSG5;
kindly provided by Dr Enrico Avvedimento), or with a
plasmid expressing dominant-negative (MH2 deletion)
Smad3 (DN-Smad3) [17]. In other transfection experi-
ments, hDF cultures were treated with 20 μg/mL neu-
tralizing pan-TGFb antibody (MAB1835, R&D System,
MN, USA). Luciferase assays were performed 16 h and
24 h after cell transfection and the results were evalu-
ated as previously described [17]. Statistical analyses
were performed for all of the experiments using Stu-
dent’s t test, assuming a P value of ≤ 0.05 as significant.
Lentiviral infections
A lentivirus expressing the wild-type proto-oncogene
Ha-Ras was generated by mutating Ha-Ras V12 coding
sequence using the quick change II site direct mutagen-
esis kit (Stratagene, CA, USA) following the manufac-
turer’s instructions. Ha-Ras coding sequence was
subcloned into the VVCW/BE lentiviral expression plas-
mid after EcoR1/EcoRV double digestion. Ha-Ras/
VVCW/BE or VVCW/BE empty vector were cotrans-
fected with CMVδR8.2 and pMD.G vectors into 293T
packaging cell line as described previously [18]. Viral
supernatants were collected 48 h and 72 h after trans-
fection and used to infect mDF cells in the presence of
10 μg/mL of polybrene.
Immunoblots and immunocyotochemistry
mDF cultured for 2 days in 0.2% FBS were infected with
Ha-Ras expressing and control lenti-particles for the
indicated length of time. In some experiments, the cul-
ture medium included neutralizing pan-TGFb antibody
or MEK inhibitor (PD98059) at concentrations of
10 μM (Calbiochem-EMD Biosciences, NJ, USA). Cell
layers were scraped into ice-cold Tris-buffered saline
solution (pH 7.4) and flash frozen in liquid nitrogen.
Cell extracts were prepared and assayed for total protein
content using the BCA kit (Pierce, IL, USA). Protein
extracts (10-25 μg / l a n e )w e r ef r a c t i o n e db y1 0 %o r6 %
(w/v) SDS-PAGE and electroblotted onto an Immobi-
lon-P membrane (Millipore, MA, USA). Membranes
were incubated first with antibodies against p-Smad3
(Invitrogen) or Smad3 (Zymed; 1:1000 dilution) and
subsequently with HRP-conjugated anti-rabbit IgG anti-
body (1:25,000 dilution; Jackson ImmunoResearch
Laboratories, PA, USA). Immunoreactive products were
visualized by chemiluminescence using the ECL Plus kit
(Amersham Biosciences, Amersham, UK) and their rela-
tive intensity was evaluated with the aid of Adobe
Photoshop software (Adobe Systems Inc, CA, USA).
Actin myofibres were visualized in cells infected with
Ha-Ras and control lentivirus using antibodies against
a-smooth muscle actin (aSMA; Chemicon, CA, USA).
RNA analyses
For real-time quantitative PCR (qPCR), total RNA was
isolated by RNeasy Mini kit (Qiagen, Hilden, Germany)
from mDF and used as template for complimentary
DNA (cDNA) synthesis (AffinityScript multiple tem-
perature reverse transcriptase, Stratagene). Target com-
plimentary DNAs were amplified using SYBR Green
Supermix with ROX (6-carboxy-X-rhodamine; Fermen-
tas) on a Mastercycler ep Realplex instrument (Eppen-
d o r f ,H a m b u r g ,G e r m a n y )a tt h ef o l l o w i n gt h e r m a l
cycling conditions: 95°C for 10 min followed by 40
cycles consisting of 95°C for 15 s denaturation, 60°C for
30 s annealing and 72°C for 30 s extension. Amplifica-
tion primer sets were purchased from SuperArray
Bioscience Corporation (Mar y l a n d ,U S A .C o m p a r a t i v e
quantification was carried out using multiple replicates
that were analysed in triplicate. Statistical significance
was evaluated by an unpaired t test assuming significant
association at P < 0.05 compared with control samples.
TGFb bioassays
Cells for TGFb bioassays (a kind gift of Dr Daniel Rifkin
[19]) were seeded at 60,000 cells/cm
2 and then incu-
bated with conditioned media collected from mDF, 6 h
and 24 h after lentiviral infection. TGFb activity was
assessed 16 h later in cell lysates by measuring luciferase
activity with a TD-20 luminometer (Turner Designs,
CA, USA) as described previously [19]. Bioassays were
performed in triplicate with multiple samples and evalu-
ated using an unpaired t test (MS Excel); significant
association was defined when P <0 . 0 5c o m p a r e dw i t h
control.
Results
Proto-oncogene Ha-Ras increases COL1A2 expression
through R-Smad activation
The first set of experiments was designed to test the
hypothesis that wild-type proto-oncogene Ha-Ras (here-
after referred solely as Ha-Ras) is directly involved in col-
lagen I stimulation and to investigate the underlying
mechanism. To this end, primary fetal hDFs were transi-
ently co-transfected with a vector expressing constitutively
active Ha-Ras (ca-Ras) and a luciferase reporter plasmid
driven by the COL1A2 proximal promoter. The results
demonstrated that ca-Ras over-expression results in a six-
fold increase of COL1A2 promoter activity (Figure 1A).
Ha-Ras over-expression similarly resulted in increased
COL1A2 promoter activity but to a lesser extent than ca-
Ras, perhaps reflecting the inherent activation of the latter
compared to the former protein (Figure 1A). Reduced
COL1A2 up-regulation in hDF co-expressing Ha-Ras and
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specificity of the former protein action (Figure 1A). More-
over, comparable amounts of the various Ha-Ras versions
excluded the formal possibility that the activity of indivi-
dual expression constructs might account for the observed
changes in the transcription from the COL1A2 promoter
(Figure 1B).
The COL1A2 proximal promoter contains a TGFb
responsive element (TbRE) that mediates transcriptional
up-regulation through the binding of a multiprotein
complex that includes R-Smads, Sp1 and p300/CBP and
that is also targeted by other pro-fibrotic stimuli, such
as those trigged by acetaldehyde, sphingolipids and
oncostatin M. [3]. Accordingly, we assessed the potential
involvement of R-Smad pathway and the TbRE in Ha-
Ras-mediated collagen up-regulation. Two lines of evi-
dence strongly suggested that Ha-Ras stimulates
COL1A2 expression, in part, through the binding of
activated R-Smad complexes to the TbRE. First, muta-
tions in the Smad3-binding site of the TbRE signifi-
cantly reduced ca-Ras up-regulation of the COL1A2
promoter (Figure 1C); second, co-transfection of a DN-
Smad3 expression plasmid abrogated ca-Ras ability to
increase COL1A2 promoter activity (Figure 1C). Once
again, immunoblots documented appreciable levels of
recombinant DN-Smad3 (Figure 1D).
The findings of the transient cell transfection experi-
ments were confirmed in quiescent mDFs that were
Figure 1 Smad3-dependent Ha-Ras activation of COL1A2 (human pro-a2( I )c o l l a g e ng e n e ) . (A) Luciferase activity (expressed as fold
induction over control sample) of the COL1A2 promoter transiently co-transfected with plasmids expressing Ha-Ras, ca-Ras or DN-Ras in
quiescent (human dermal fibroblast) hDF cultures (B) Western blot analyses of recombinant Ha-Ras, ca-Ras and DN-Ras levels in hDF cells (n =3
per each sample) using anti-Ha-Ras antibodies. (C) Luciferase activity (expressed as fold induction over control sample) of wild-type and TbRE
[transforming growth factor-b (TGFb)-responsive element] mutated COL1A2 promoter constructs transiently co-transfected in quiescent hDF
cultures with the indicated combinations of ca-Ras expressing plasmid or the DN-Smad3 expression vector; cells stimulated with recombinant
TGFb1 (2 ng/mL) served as a positive control. (D) Western blot analysis of recombinant DN-Smad3 levels in hDF cells (n = 3 per each sample)
using anti-Smad3 antibodies. Luciferase values in panels A and C represent the average of three independent transfections each performed in
duplicate. Error bars signify ± standard deviation and asterisks indicate statistically significant differences (P < 0.05).
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Ha-Ras. Specifically, these analyses showed that Ha-
Ras expressing mDF display augmented Smad3 phos-
phorylation and Smad3-reporter plasmid activity (Fig-
ure 2A) and collagen I production and COL1A2
promoter transcription (Figure 2B and 2F), as well as
more cells expressing contraction-competent actin
myofibres compared to mDF infected with control
lentivirus (Figure 2C). An additional outcome of Ha-
Ras overexpression in mDF cells included the rapid
activation of ERK1/2 signalling (Figure 2A), which is
part of the self-propagating loop of ROS production,
Ha-Ras stabilization and collagen I accumulation in
SSc [15,16] and also of JNK and p38 MAPK (data
not shown). As a result of its participation in SSc
pathogenesis [15,16], ERK1/2 signalling in Ha-Ras
Figure 2 Activated phenotype of mouse dermal fibroblast (mDF) constitutively expressing Ha-Ras. (A) Left panel, pSmad3, Smad3, pERK1/
2, ERK1/2, Ha-Ras and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) immunoblots of protein extracts from mDF cultures infected with
Ha-Ras (Ha-Ras lenti) or control (lenti) lentiviruses at 6 h post-infection (n = 3 per each sample) with the bar graphs on the side summarizing the
relative ratios of pSmad3 over GADPH and pERK1/2 over ERK1/2; right panel, luciferase activity of a Smad3-responsive plasmid transiently
transfected in mDF infected with Ha-Ras or control lentivirus and/or stimulated with recombinant transforming growth factor-b (TGFb1; 2 ng/
mL) for 6 h. (B) Collagen I and Ha-Ras immunoblots of protein extracts from mDF cultures infected with Ha-Ras or control lentiviruses at 24 h
post-infection and in control cells treated with recombinant TGFb1 (2 ng/mL) for the same length of time (n = 3 per each sample). (C) a-
smooth muscle actin (aSMA) immunostaining of mDF infected with Ha-Ras or control lentiviruses with bar graphs on the side summarizing the
percentage of aSMA-positive cells 24 h after the infection; measurements were performed on >100 cells from three independent infections. (D)
pSmad3 immunoblots of protein extracts from mDF cultures treated with the MEK inhibitor PD98059 (10 μM) for 2 h prior to infection for 6 h
with Ha-Ras or control lentiviruses with bar graphs on the side summarizing the relative ratio of pSmad3 and the loading control GADPH in the
various experimental samples (n = 3 per each sample). (E) Collagen I immunoblots of protein extracts from mDF cultures treated with the MEK
inhibitor PD98059 (10 μM) for 2 h prior to infection with Ha-Ras or control lentiviruses (n = 3 per each sample); protein levels were assessed
24 h post-infection and the bar graphs on the side summarize the relative ratio of collagen I and the loading control GADPH in the various
experimental samples. (F) Luciferase activity (expressed as fold induction over control sample) of the COL1A2 promoter plasmid transiently
transfected in primary mDF infected with Ha-Ras or control lentiviruses at 24 h post-infection with or without 2 h pre-treatment with the MEK
inhibitor PD98059 (10 μM). In the relevant panels, arrows and arrowheads point to Ha-Ras and a non-specific immunoreactive products or
pSmad3 and an unidentified cross-reacting R-Smad, respectively; luciferase values represent the average of three independent transfections each
performed in duplicate; error bars signify ± standard deviation and asterisks indicate statistically significant differences (P < 0.05).
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inhibitor PD98059. However, ERK1/2 inhibition had
no effect on Ha-Ras-induced stimulation of R-Smad sig-
nalling, COL1A2 promoter transcription or collagen I accu-
mulation (Figure 2D-F). Time-point analyses further
revealed that R-Smad stimulation is transient and peaks 6 h
after mDF infection, whereas collagen I protein levels
remain elevated up to 24 h (Figure 3A and 3B). Interest-
ingly, Ha-Ras-expressing cells also exhibited high protein
levels of non-phosphorylated Smad3 at 6 h and 24 h post-
infection, which were not, however, associated with
increased levels of transcripts coding for Smad3 (Figure
3C). We interpreted these last results to suggest that
greater amounts of available Smad3 protein may also con-
tribute to heightened pSmad3.
Proto-oncogene Ha-Ras induces collagen up-regulation
independently of TGFb
Several reports have shown that Ha-Ras promotes
autocrine TGFb signalling [6,7,20]. The possible con-
tribution of Ha-Ras to TGFb production and, in turn,
collagen I synthesis was therefore investigated in our
cell culture systems. To this end, a pan-TGFb antibody
was employed in two complementary experiments
which documented the inability of TGFb antagonism
to normalize COL1A2 promoter activity in quiescent
hDF cultures transiently co-transfected with the ca-Ras
expressing plasmid and in mDF cells stably infected
with the Ha-Ras lentivirus (Figure 4A and 4B). These
findings excluded the potential involvement of TGFb
neo-synthesis in Ha-Ras up-regulation of collagen I
expression. Next, we evaluated whether Ha-Ras overex-
pression may promote improper activation of latent
TGFb complexes as opposed to TGFb neo-synthesis. A
bioassay, however, revealed comparable levels of active
TGFb in control and Ha-Ras over-expressing mDF
cells (Figure 5A). Consistent with this and the above
findings, qPCR analyses showed similar levels of TGFb
transcripts in control and Ha-Ras over-expressing mDF
cells (Figure 5B). Collectively, the data suggested that
increase of Ha-Ras protein levels in dermal fibroblasts
promotes an immediate fibrotic response through the
canonical R-Smad pathway without establishing an
autocrine TGFb loop.
Figure 3 pSmad3 and collagen type I kinetics in Ha-Ras-infected mouse dermal fibroblast (mDF). (A) pSmad3 and Smad3 and (B)
collagen I immunoblots (n = 3 per each sample) of protein extracts prepared at the indicated time points after infection of mDF cultures with
Ha-Ras or control lentiviruses with bar graphs on the side summarizing the ratios of pSmad3 or collagen I relative to the loading control
glyceraldehyde 3-phosphate dehydrogenase (GADPH) in the various experimental samples; asterisks indicate statistically significant differences (P
< 0.05). (C) Real-time quantitative polymerase chain reaction (qPCR) estimates of Smad3 transcript levels in mDF cultures infected with Ha-Ras or
control lentiviruses. In the first panel, the arrow and arrowhead respectively point to pSmad3 and an unidentified cross-reacting receptor-
activated Smad (R-Smad).
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Accumulation of myofibroblasts and disorganized ECM
are the hallmarks of tissue fibrosis. TGFb is a potent
inducer of ECM synthesis and myofibroblasts contrac-
tion and a key mediator of wound healing and fibrotic
responses [2]. However, TGFb pleiotropy has largely
limited therapeutical intervention in fibrotic diseases,
thus stimulating an increased interest in the identifica-
tion of pro-fibrotic pathways that operate downstream,
upstream or in parallel with TGFb signalling [2]. Data
presented here implicate Ha-Ras stabilization in the
early onset of fibrosis through TGFb-independent sti-
mulation of R-Smad signalling.
Previous reports that Ha-Ras proto-oncogene inter-
sects with TGFb signalling events in several fibrotic con-
ditions [8,9], together with recent evidence that
scleroderma auto-antibodies stabilize Ha-Ras levels
through ROS action [15,16], led us to hypothesize that
increased Ha-Ras activity may influence TGFb signalling
during the early phase of the pro-fibrotic response.
Through Ha-Ras overexpression in quiescent mDF, we
have demonstrated that the proto-oncogene directly up-
regulates collagen production through TGFb-indepen-
dent activation of the canonical R-Smad pathway.
Three independent lines of evidence support our con-
clusion. First, forced expression of DN-Smad3 and
mutations in the TbRE of the COL1A2 promoter signifi-
cantly reduced Ha-Ras-dependent up-regulation of the
reporter plasmid. Second, lentiviral overexpression of
Ha-Ras rapidly increased Smad3 signalling and R-Smad-
dependent reporter activity. Third, mDF pre-treatment
with neutralizing pan-TGFb antibody, or with a MEK
Figure 4 Ha-Ras up-regulates collagen I independently of autocrine transforming growth factor-b (TGFb). (A) Luciferase activity
(expressed as fold induction over control sample) of the human pro-a2 (I) collagen gene (COL1A2) promoter co-transfected with the ca-Ras
expressing plasmid in quiescent human dermal fibroblast (hDF) cultured in the presence or absence of TGFb neutralizing antibody (2 and 10 μg/
mL); cells stimulated with recombinant TGFb1 (2 ng/mL) served as a positive control. Luciferase values represent the average of three
independent transfections each performed in duplicate and error bars signify ± standard deviation and asterisks indicate statistically significant
differences (P < 0.05). (B) Collagen I immunoblots of protein extracts (n = 3 per each sample) from mouse dermal fibroblast (mDF) cultures
infected with Ha-Ras or control lentiviruses and cultured in the presence or absence of TGFb neutralizing antibody (10 μg/mL) for the indicated
times. (C) pSmad3 immunoblots of protein extracts (n = 3 per each sample) from mDF cultures stimulated with recombinant TGFb1 (2 ng/mL) in
the presence or absence of neutralizing TGFb antibodies (10 μg/mL). In the last two panels, bar graphs summarize the ratio of pSmad3 or
collagen I relative to the loading control glyceraldehyde 3-phosphate dehydrogenase (GADPH) in the various experimental samples; asterisks
indicate statistically significant differences (P < 0.05).
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accumulation and Ha-Ras-induced R-Smad activation.
These results are in agreement with previous reports
indicating that ligand-independent R-Smad signalling is
increased in scleroderma cells and that Ha-Ras-depen-
dent MAPK stimulation is not required for R-Smad acti-
vation [10,21]. In contrast to the reported participation
of ERK1/2 signalling in perpetuating ROS and Ha-Ras
stimulation of collagen I production in SSc fibroblasts
[15,16], ERK1/2 signalling is not required for collagen I
up-regulation in Ha-Ras over-expressing cells. This
apparent discrepancy suggests that constitutively high
levels of Ha-Ras in our cell culture system do not
require the postulated feed-forward loop of ERK1/2 sig-
nalling [15,16]; implicitly, our conclusion suggests that
the amount of Ha-Ras is a limiting factor during the
early phase of SSc fibrosis.
Protein turnover is another modulator of R-Smad3
activity in addition to protein phosphorylation [4]. The
finding that Ha-Ras overexpression in mDF is associated
with increased Smad3 protein levels and normal
amounts of Smad3 transcripts strongly suggests
decreased protein degradatio n .R e c e n t l y ,t h ep r o t e i n
kinase GSK3b has been shown to control Smad3 ubiqui-
tination and degradation [22]. GSK3b activity is nega-
tively regulated by Ras family members and fibroblast-
specific deletion of GSK3b in mice results in accelerated
wound closure, increased fibrogenesis and excessive
scarring [23,24]. Altogether, these reports and our
results are at least consistent with the notion that aug-
mented Smad stability in mDF overexpressing Ha-Ras
accounts in part for the ligand-independent increase of
canonical TGFb signalling and collagen production. A
similar situation has been described for SSc fibroblasts
in which higher than normal levels of Smad3 and Ha-
Ras proteins are both associated with increased collagen
accumulation [16,21].
In contrast with our observations, others have
reported that oncogenic Ha-Ras (V12-Ha-Ras) dictates
the response of cancer cells to TGFb by decreasing
Smad3 stability, thus suggesting a negative role of Ha-
Ras in modulating R-Smad signalling [25]. Moreover,
Ha-Ras has been shown to inhibit R-Smad activity in
epithelial cells and to down-regulate collagen expression
in proliferating fibroblasts [26,27]. We believe that these
apparent discrepancies probably reflect the multiple
roles that Ha-Ras plays in integrating the contextual
responses of cells to TGFb signalling. Our results con-
tribute to the ongoing efforts to dissect the complex
n e t w o r ko fs i g n a l l i n ge v e n t st h a td r i v et h eo n s e ta n d
progression of tissue fibrosis.
Conclusions
Our results provide a mechanistic insight into the role
of Ha-Ras stabilization in driving collagen I overpro-
duction during the early phase of dermal fibrosis in
Figure 5 Normal transforming growth factor-b (TGFb) levels and activity in Ha-Ras infected mouse dermal fibroblasts (mDFs).( A )
Cell-based bioassays estimating the amount of active TGFb in mDF cultures infected with Ha-Ras or control lentiviruses. (B) Real-time
quantitative polymerase chain reaction (qPCR) assessment (n =3 )o fs t e a d y - s t a t el e v e l so fT G F b messenger RNAs in mDF cultures infected
with Ha-Ras or control lentiviruses. Each bar graph represents three independent samples analysed in duplicate and error bars signify ±
standard deviation.
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oncogene in stimulating R-Smad signalling indepen-
dently of TGFb neo-synthesis or activation and of
ERK1/2 signalling. This conclusion is based on in vitro
evidence that correlated Ha-Ras-induced activation of
R-Smad directly to the stimulation of COL1A2 promo-
ter reporter plasmid and with the elevation of endo-
genous collagen I protein. Together, our findings
extend and refine recent reports that implicated circu-
lating PDFR auto-antibody in the triggering of the
ROS-mediated stabilization of Ha-Ras activity in SSc
[15,16]. As such, they contribute to a better under-
standing of the early signalling events and potential
therapeutic opportunities in this acquired disabling
disorder of the connective tissue.
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